RAD December 2020 Abstracts - Page 4


#362 - Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Open-Label Run-In Period of JADE REGIMEN

Mark G. Lebwohl, Margitta Worm, Linda F. Stein Gold, Christine Bangert, Peter Schmid-Grendelmeier, Tahira Khan, Pinaki Biswas, Marco DiBonaventura, Gary Chan, Ketti Terry, Hernan Valdez, Claire Clibborn8


#364 - Content Validity of the Atopic Dermatitis Symptom Scale (ADerm-SS) and Atopic Dermatitis Impact Scale (ADerm-IS) in Adolescents to Assess the Symptoms and Impacts of Atopic Dermatitis

Jonathan I. Silverberg, Eric L. Simpson, Megan McLafferty, Sylvia Su, Paolo Medrano, Brian M. Calimlim, Amy S. Paller 


#365 - Psychometric Evaluation of Three Patient-Reported Outcome Questionnaires Assessing the Symptoms and Impacts of Atopic Dermatitis in Adults and Adolescents

Jonathan I. Silverberg, Eric L. Simpson, Leighann Litcher-Kelly, Jeffrey McDonald, Brian M. Calimlim, Yael A. Leshem


#366 - Consistent Efficacy Responses of Abrocitinib Monotherapy Across Randomized Controlled Phase 2/3 Clinical Trials: Results From JADE MONO-1, JADE MONO-2, and the Phase 2b Proof-of-Concept Trial 

Eric L. Simpson, Melinda J. Gooderham, Jacob P. Thyssen, Gary Chan, Svitlana Tatulych, Pinaki Biswas, Sarah Ofori, Andrew Thorpe, Ricardo Rojo


#367 - Examining the Relationships Among Abrocitinib Monotherapy, Pruritus Severity, and Skin Clearance in Patients With Moderate-to-Severe Atopic Dermatitis: Results From JADE MONO-1 and JADE MONO-2

Eric L. Simpson, Gil Yosipovitch, Sonja Ständer, Jonathan I. Silverberg, Jacob P. Thyssen, Shawn G. Kwatra, Thomas Luger, Emma Guttman-Yassky, Wynnis L. Tom, Andrew G. Bushmakin, Joseph C. Cappelleri, Gary Chan, Claire Feeney, Natalie Yin, Hernan Valdez, Marco DiBonaventura, Daniela E. Myers


#368 - Positive Psychology (PERMA) Themes in Interviews of Children with Atopic Dermatitis

Terry M. Lou, Kenneth L. Zhang, Noel Slesinger, Michelle Taddeo, Eloisa Serrano, Amy S. Paller, James W. Griffith, Anna B. Fishbein


#369 - Sleep Health and Attention Dysregulation in a National Study of Infants and Preschool Aged Children with Atopic Dermatitis (AD)

Nina Y. Zhou, BA, Amanda Nili, BA, Courtney Blackwell, PhD, Nonye Ogbuefi, BA, Peter Cummings, MPH, Jin-Shei Lai, PhD, OTR, James W. Griffith, PhD, Amy S. Paller, MD, MS, Lauren Wakschlag, PhD, Anna B. Fishbein, MD, MS


#371 - Persistence and adherence with dupilumab therapy in patients with atopic dermatitis (AD): A single-center experience

Mindy R. Hong, PhD, MSPH, Jonathan I. Silverberg, MD, PhD, MPH


#375 - Tralokinumab prevents flares in moderate-to-severe atopic dermatitis: post hoc analyses of a randomized phase 3 clinical trial (ECZTRA 3)

Jonathan I. Silverberg, Sebastien Barbarot, Julia Welzel, Mahreen Ameen, Jacob P. Thyssen, Mark Lomaga, Christina Kurre Olsen, Thomas Mark, Joshua Corriveau, and Joseph F. Merola


#376 - Real-world burden of comorbidities of atopic dermatitis in the U.S. adult population

Youkyung S Roh BA, Amy H Huang MD MPH, Nishadh Sutaria BS, Deepa Patel MD, Justin Choi BA, Joseph K Canner MHS, Shawn G Kwatra MD


© 2021 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.